Pyxis Oncology (PYXS) Accumulated Expenses (2020 - 2025)

Pyxis Oncology (PYXS) has 6 years of Accumulated Expenses data on file, last reported at $8.6 million in Q4 2025.

• On a quarterly basis, Accumulated Expenses fell 24.77% year-over-year to $8.6 million in Q4 2025; TTM through Dec 2025 was $8.6 million, a 24.77% decrease from a year earlier, with the FY2025 full-year figure at $8.6 million, down 24.77% from the prior year.
• Accumulated Expenses for Q4 2025 stood at $8.6 million, up from $8.0 million in the prior quarter.
• Over the last five years, Accumulated Expenses for PYXS reached as high as $17.1 million in Q1 2022 and fell as low as $4.2 million in Q4 2022.
• Historically, Accumulated Expenses has averaged $9.4 million across 5 years, with a median of $8.3 million in 2025.
• Across the five-year window, Accumulated Expenses surged 230.1% in 2021 and plunged 62.86% in 2023, its largest moves.
• Year by year, Accumulated Expenses stood at $6.6 million in 2021, then plunged by 35.71% to $4.2 million in 2022, then rose by 23.15% to $5.2 million in 2023, then soared by 117.88% to $11.4 million in 2024, then fell by 24.77% to $8.6 million in 2025.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $8.6 million in Q4 2025, $8.0 million in Q3 2025, and $6.7 million in Q2 2025.